Changing the future of Oncology.


Open Letter From Our CEO

Today, I want to clearly state, that America still has a very long way to go to fulfill the hard won promises of the Civil Rights era of the 60s. I was born in 1957 and so was first exposed to civil rights issues as a child. But I was from an aspiring middle class...

read more

Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity

Additionally, Sutro’s partner Merck KGaA, Darmstadt, Germany, will be unveiling preclinical data from the collaboration’s pre-Development Candidate, a first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1 SOUTH SAN FRANCISCO, Calif., June 22, 2020...

read more

SutroVax Announces Name Change to Vaxcyte

Foster City, Calif., May 21, 2020 – SutroVax, Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc. The new name more accurately reflects the Company’s mission to improve global health by developing superior and novel...

read more